Despite advances in immunotherapy, clinical trials targeting PD-1/PD-L1 in ovarian cancer have shown limited efficacy, underscoring the need for novel strategies that disrupt Treg-mediated immunosuppression. The gene discussed is CD274; the disease is ovarian carcinoma.